Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Roles of tyrosine residues 845, 892 and 922 in constitutive activation of murine FLT3 kinase domain mutant

Abstract

FLT3 tyrosine kinase domain (TKD) mutations are detected in 7% of acute myeloid leukemia patients, and suggested to correlate with poor prognosis and confer resistance to FLT3 inhibitors. To explore activation mechanism of FLT3 TKD mutation, we analysed critical tyrosine residues for the constitutive activation and downstream signaling of the mutant by generating a series of single Tyr → Phe substitution mutant of all 22 cytoplasmic tyrosine residues of murine FLT3 TKD-mutant (mFLT3Asp838Val). Tyr845Phe, Tyr892Phe and Tyr922Phe substitutions suppressed the phosphorylation of mFLT3Asp838Val itself, the activation of Erk1/2, STAT3 and STAT5, and the factor-independent cell proliferation and survival. In contrast, these three Tyr → Phe mutations partially suppressed but maintained the ligand-dependent activation and anti-apoptotic activity of wild-type FLT3, suggesting that these tyrosine residues were more critical for the constitutive activation and signaling of mFLT3Asp838Val. These three Tyr → Phe mutations also inhibited the constitutive activation of other FLT3 mutants bearing internal tandem duplication, Asp838Tyr or Ile839del. The suppression of mFLT3Asp838Val activation and signaling by these substitutions was partially recovered by shifting the culture temperature from 37 to 33°C, or by the introduction of Cdc37 and Hsp90. Taken together, Tyr845, Tyr892 and Tyr922 are the critical residues in mFLT3Asp838Val activation, possibly through stabilizing the active conformation of mFLT3Asp838Val.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR and Reilly JT . (2001). Br. J. Haematol., 113, 983–988.

  • Abu-Duhier FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC, Vandenberghe EA, Winship PR and Reilly JT . (2000). Br. J. Haematol., 111, 190–195.

  • Beslu N, LaRose J, Casteran N, Birnbaum D, Lecocq E, Dubreuil P and Rottapel R . (1996). J. Biol. Chem., 271, 20075–20081.

  • Care RS, Valk PJ, Goodeve AC, Abu-Duhier FM, Geertsma-Kleinekoort WM, Wilson GA, Gari MA, Peake IR, Lowenberg B and Reilly JT . (2003). Br. J. Haematol., 121, 775–777.

  • Carlesso N, Griffin JD and Druker BJ . (1994). Oncogene, 9, 149–156.

  • Fenski R, Flesch K, Serve S, Mizuki M, Oelmann E, Kratz-Albers K, Kienast J, Leo R, Schwartz S, Berdel WE and Serve H . (2000). Br. J. Haematol., 108, 322–330.

  • Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, Matsuzawa Y, Kitamura Y and Kanakura Y . (1993). J. Clin. Invest., 92, 1736–1744.

  • Griffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J and Saxena K . (2004). Mol. Cell., 13, 169–178.

  • Grundler R, Thiede C, Miething C, Steudel C, Peschel C and Duyster J . (2003). Blood, 102, 646–651.

  • Hashimoto K, Matsumura I, Tsujimura T, Kim DK, Ogihara H, Ikeda H, Ueda S, Mizuki M, Sugahara H, Shibayama H, Kitamura Y and Kanakura Y . (2003). Blood, 101, 1094–1102.

  • Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD and Fletcher JA . (2003). Science, 299, 708–710.

  • Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y and Kitamura Y . (2003). Gastroenterology, 125, 660–667.

  • Hubbard SR . (1997). EMBO J., 16, 5572–5581.

  • Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R and Ueda R . (1999). Blood, 93, 3074–3080.

  • Li S, Covino ND, Stein EG, Till JH and Hubbard SR . (2003). J. Biol. Chem., 278, 26007–26014.

  • Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, Duffy T, Jacobs P, Tang LH and Modlin I . (1996). Nat. Genet., 12, 312–314.

  • Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G and Longley BJ . (2002). Blood, 99, 1741–1744.

  • Mayer BJ, Jove R, Krane JF, Poirier F, Calothy G and Hanafusa H . (1986). J. Virol., 60, 858–867.

  • Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, Steffen B, Matsumura I, Kanakura Y, Bohmer FD, Muller-Tidow C, Berdel WE and Serve H . (2003). Blood, 101, 3164–3173.

  • Mohammadi M, Schlessinger J and Hubbard SR . (1996). Cell, 86, 577–587.

  • Moreno I, Martin G, Bolufer P, Barragan E, Rueda E, Roman J, Fernandez P, Leon P, Mena A, Cervera J, Torres A and Sanz MA . (2003). Haematologica, 88, 19–24.

  • Morita S, Kojima T and Kitamura T . (2000). Gene Theraphy, 7, 1063–1066.

  • Muller C, Readhead C, Diederichs S, Idos G, Yang R, Tidow N, Serve H, Berdel WE and Koeffler HP . (2000). Mol. Cell. Biol., 20, 3316–3329.

  • Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T and Misawa S . (1996). Leukemia, 10, 1911–1918.

  • Reilly JT . (2002). Br. J. Haematol., 116, 744–757.

  • Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Loffler H, Sauerland CM, Serve H, Buchner T, Haferlach T and Hiddemann W . (2002). Blood, 100, 59–66.

  • Scholz G, Hartson SD, Cartledge K, Hall N, Shao J, Dunn AR and Matts RL . (2000). Mol. Cell. Biol., 20, 6984–6995.

  • Scholz GM, Hartson SD, Cartledge K, Volk L, Matts RL and Dunn AR . (2001). Cell Growth Differ., 12, 409–417.

  • Spiekermann K, Dirschinger RJ, Schwab R, Bagrintseva K, Faber F, Buske C, Schnittger S, Kelly LM, Gilliland DG and Hiddemann W . (2003). Blood, 101, 1494–1504.

  • Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M, Neubauer A, Ehninger G and Illmer T . (2002). Blood, 99, 4326–4335.

  • Ueda S, Ikeda H, Mizuki M and Ishiko J . (2002). Int. J. Hematol., 76, 427–435.

  • Worobec AS, Semere T, Nagata H and Metcalfe DD . (1998). Cancer, 83, 2120–2129.

  • Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R and Naoe T . (2001). Blood, 97, 2434–2439.

  • Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, Sonoda Y, Abe T, Kahsima K, Matsuo Y and Naoe T . (1997). Leukemia, 11, 1605–1609.

  • Yu JC, Apatira M, Li J, Clauser K, Sullivan C, Lokker N and Giese NA . (2003). Blood, 102, 348a (abstract #1260).

Download references

Acknowledgements

This work is supported by grants from the Japanese Ministry of Education, Culture, Sports, Science and Technology, and Japan Society for the Promotion of Science, from the Ichiro Kanehara Foundation, and from the NH&MRC (Australia).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Masao Mizuki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ishiko, J., Mizuki, M., Matsumura, I. et al. Roles of tyrosine residues 845, 892 and 922 in constitutive activation of murine FLT3 kinase domain mutant. Oncogene 24, 8144–8153 (2005). https://doi.org/10.1038/sj.onc.1208957

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208957

Keywords

This article is cited by

Search

Quick links